Vaginal Changes After CO2 Laser

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a treatment called CO2 laser therapy for women experiencing genitourinary syndrome of menopause (GSM). GSM is a condition that occurs when estrogen levels drop during menopause, leading to symptoms like vaginal dryness, burning, painful intercourse, and urinary issues. The trial aims to see how effective the laser treatment is by comparing women who receive the therapy with those who do not receive any treatment (a sham group). Researchers will use a special imaging technology to observe changes in the vaginal tissue and will also ask participants to complete questionnaires about their symptoms.

To be eligible for this trial, participants must be women aged 18 and older who are postmenopausal and interested in laser therapy for GSM. They should not be on hormone replacement therapy or have certain medical histories, such as pelvic radiation or recurrent urinary tract infections. If you join the study, you will have the opportunity to receive laser treatment and help researchers learn more about non-hormonal options for managing GSM.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Birth sex: female
• • 2. Desire for vaginal laser therapy for GSM
• • 3. Age \>=18 years old
• • 4. Willingness to forego other treatments for GSM within the study period
• • 5. Diagnosed as postmenopausal (either by surgical removal of ovaries or natural progression defined as no periods in 1 year)
• Exclusion Criteria:
• • 1. History of pelvic radiation
• • 2. On hormone replacement therapy in the prior 3 months
• • 3. Not able or willing to follow study instructions
• • 4. Current diagnosis of recurrent UTIs